•Registration opens for Corneal Health Summit 2026• FDA accepts sNDA of phentolamine 0.75% for presbyopia •Vision Source launches member dividends initiative program•AGS 2026 highlights best practices for surgery and new, evidence-based innovations•Neurolens with Contoured Prism tech demonstrates greater symptom relief for binocular vision anomalies •Registration opens for Corneal Health Summit 2026• FDA accepts sNDA of phentolamine 0.75% for presbyopia •Vision Source launches member dividends initiative program•AGS 2026 highlights best practices for surgery and new, evidence-based innovations•Neurolens with Contoured Prism tech demonstrates greater symptom relief for binocular vision anomalies
HEADLINES
FEATURED
New guidance ends a long-standing reliance on the “two-trial dogma,” potentially lowering capital costs for drug developers and prices for patients.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
